Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71815 | 0.94 | CYP2C9 (0.61) | CYP2C9CYP2D6HIF1AMEN1KMT2A | |
| SCHEMBL4619076 | 0.91 | CYP2C9 (0.55) | CYP2C9CYP2D6HIF1AMEN1KMT2A | |
| Bromomethane SCHEMBL3169377 | 0.89 | CYP2C9 (0.57) | CYP2C9CYP2D6HIF1AMEN1KMT2A | |
| Benzylic Acid SCHEMBL7066 | 0.87 | CYP2C9 (0.74) | CYP2C9CYP2D6HIF1AKMT2AHTT | |
| Benzylic Acid SCHEMBL4823051 | 0.85 | CYP2C9 (0.65) | CYP2C9CYP2D6HIF1AMEN1KMT2A | |
| Benzylic Acid SCHEMBL1680669 | 0.84 | CYP2C9 (0.71) | CYP2C9CYP2D6HIF1AMEN1KMT2A | |
| Benzylic Acid SCHEMBL9181980 | 0.84 | CYP2C9 (0.71) | CYP2C9CYP2D6HIF1AMEN1KMT2A | |
| Benzylic Acid SCHEMBL20957595 | 0.84 | CYP2C9 (0.71) | CYP2C9CYP2D6HIF1AMEN1KMT2A | |
| Benzylic Acid SCHEMBL1681667 | 0.84 | CYP2C9 (0.71) | CYP2C9CYP2D6HIF1AMEN1KMT2A | |
| Benzylic Acid SCHEMBL868225 | 0.84 | CYP2C9 (0.71) | CYP2C9CYP2D6HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108901-A | Synthetic method of alpha-hydroxycarboxylic acid compound | 四川大学 | 2022-09-27 | — | — | CN | disclosed |
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
| US-5776964-A | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-07 | — | — | US | disclosed |
| US-5521206-A | HYPOTENSIVE AGENTS, TREATMENT OF ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |
| US-5274104-A | N-substituted heterocyclic derivatives useful in the treatment of cardiovascular disorders | ELF SANOFI, A FRENCH CORP. (FR) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CYP2C9 437/4885CYP2D6 136/4885HIF1A 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.